menu
    • menu
    [{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Covis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Ferumoxytol","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"AMAG Pharmaceuticals","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.65000000000000002,"dosageForm":"Intravenous Injection","sponsorNew":"AMAG Pharmaceuticals \/ Covis","highestDevelopmentStatusID":"12","companyTruncated":"AMAG Pharmaceuticals \/ Covis"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Covis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"","productType":"Small molecule","year":"2020","type":"Acquisition","leadProduct":"Ferumoxytol","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"AMAG Pharmaceuticals","amount2":0.65000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0.65000000000000002,"dosageForm":"","sponsorNew":"AMAG Pharmaceuticals \/ Covis Group","highestDevelopmentStatusID":"12","companyTruncated":"AMAG Pharmaceuticals \/ Covis Group"}]

    Find Clinical Drug Pipeline Developments & Deals for Ferumoxytol

    Menu

    Ferumoxytol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            AMAG Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            AMAG Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferumoxytol

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Covis Pharma

                            Deal Size : $647.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Covis Group Completes Acquisition of AMAG Pharmaceuticals

                            Details : The acquisition adds AMAG's key products Feraheme®, Makena® and Ciraparantag to Covis' pipeline as it carries out its mission of expanding patient access to much needed therapies.

                            Brand Name : Feraheme

                            Molecule Type : Small molecule

                            Upfront Cash : $647.0 million

                            November 16, 2020

                            Lead Product(s) : Ferumoxytol

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Covis Pharma

                            Deal Size : $647.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AMAG Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            AMAG Pharmaceuticals

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferumoxytol

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Covis Pharma

                            Deal Size : $647.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Covis Group Announces Agreement to Acquire AMAG Pharmaceuticals

                            Details : With this deal, Covis gains access to AMAG’s two commercial therapies, Makena, indicated for women with risk of preterm birth in singleton pregnancies and Feraheme indicated treat iron deficiency anaemia in CKD patients and for whom oral iron is not su...

                            Brand Name : Feraheme

                            Molecule Type : Small molecule

                            Upfront Cash : $647.0 million

                            October 01, 2020

                            Lead Product(s) : Ferumoxytol

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Covis Pharma

                            Deal Size : $647.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth